NASDAQ$CCCC
C4 Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter and recent business highlights.
C4 Therapeutics reported a net loss of $28.4 million for the first quarter of 2024, with total revenue of $3.0 million. The company's cash, cash equivalents, and marketable securities totaled $299.2 million as of March 31, 2024, expected to provide runway into 2027. They delivered a development candidate to Biogen, earning an $8 million payment, and established a strategic discovery research collaboration with Merck KGaA, Darmstadt, Germany.
- Delivered first development candidate to Biogen, earning an $8 million payment.
- Established a strategic discovery research collaboration with Merck KGaA, Darmstadt, Germany, focused on two critical oncogenic proteins.
- Advanced Phase 1 dose escalation trials for Cemsidomide (CFT7455) and CFT1946, with data from both trials expected in 2H 2024.
- Cash, cash equivalents and marketable securities totaled $299.2 million as of March 31, 2024, expected to provide runway into 2027.
Headline financials
Revenue & EPS history
C4 Therapeutics · Revenue · Quarterly
$3.04M
Revenue by segment
C4 Therapeutics · $11.1M total across 1 segment · Q3 2023
- Collaboration agreements$11.1M+63.9%100.0%
Forward guidance
C4T expects that its cash, cash equivalents and marketable securities as of March 31, 2024 will be sufficient to fund planned operating expenses and capital expenditures into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+1.0%
Avg return
Earnings day
+4.1%
Avg return
5 days after
-1.1%
Avg return
30 days after
38%
9 / 24 earnings
Positive
+24.0%
Q4 2023
Best reaction
-10.0%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +13.0% | +22.2% | |
| Q4 2025 | +0.4% | +17.4% | +13.9% | |
| Q3 2025 | -2.0% | -10.0% | +8.0% | |
| Q1 2025 | -0.7% | -1.4% | +21.7% | |
| Q4 2024 | -1.9% | -10.2% | -34.0% | |
| Q3 2024 | +1.4% | +10.1% | -17.7% | |
| Q1 2024 | +0.1% | -9.1% | -31.4% | |
| Q4 2023 | +24.0% | +34.5% | +13.4% | |
| Q3 2023 | -6.0% | +21.5% | +7.4% | |
| Q2 2023 | -1.7% | -3.1% | -33.8% | |
| Q1 2023 | +4.8% | +5.6% | +8.0% | |
| Q4 2022 | -10.0% | -11.0% | -40.2% | |
| Q3 2022 | -8.1% | -6.4% | -11.8% | |
| Q2 2022 | +16.7% | +6.9% | -8.7% | |
| Q1 2022 | -8.1% | -19.3% | -24.4% | |
| Q4 2021 | +13.9% | +13.9% | +24.3% | |
| Q3 2021 | -4.6% | -7.3% | -23.6% | |
| Q2 2021 | +8.0% | +5.6% | +33.6% | |
| Q1 2020 | -0.6% | +7.4% | +20.4% | |
| Q1 2021 | -0.6% | +7.4% | +20.4% | |
| Q2 2020 | +9.6% | +7.2% | -19.8% | |
| Q3 2019 | -3.7% | +8.3% | +8.3% | |
| Q3 2020 | -3.7% | +8.3% | +8.3% | |
| Q4 2019 | -3.7% | +8.3% | +8.3% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro